Riskpilot← Back to searchSign inGet full accessMedFer AB
ABActiveOrg 5591732010Önologgatan 2 Lgh 1104Medical specialists activities · NACE 8622Est. 20181-4 employees
Revenue 2024
SEK 197K
+66% vs 2023
EBITDA margin
1.3%
+186% vs 2023
Equity ratio
94.9%
Financial strength
Net profit 2024
SEK -4K
-20% vs 2023
| Revenue | SEK 197K | +66% |
| EBITDA | SEK 3K | +186% |
| Net profit | SEK -4K | -20% |
| Total assets | SEK 101K | -62% |
| Equity | SEK 96K | -17% |
| Employees | — | — |
Legal name
MedFer AB
Org number
5591732010
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
27 september 2018
Share capital
SEK 50 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget bedriver föreläsningar och utbildning inom sjukvård, första hjälpen och hjärt- lungräddning för personal inom hälso- och sjukvård och privata företag. Inspirations- och motivationsföreläsningar för elever på högstadiet, gymnasiet, högskolor och andra verksamheter. Även sjukvårdskonsult, arbeta som specialistsjuksköterska, samt bedriva skönhetsvård och behandlingar.
Address
Önologgatan 2 Lgh 1104
Email
ferhat@medfer.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 47 | — | 6 | 119 | 197 |
| Staff expenses | — | — | −17 | −54 | −22 |
| EBITDA | 28 | 0 | −58 | −3 | 3 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 28 | 0 | −58 | −3 | 3 |
| Net financials | — | — | — | — | −6 |
| Profit before tax | 28 | 0 | −58 | −3 | −3 |
| Tax | −6 | — | — | — | −0 |
| Net profit | 22 | — | −58 | −3 | −4 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 92 | — | 254 | 266 | 101 |
| Equity | 72 | — | 119 | 116 | 96 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 20 | — | 135 | 150 | 5 |
| Total debt | 20 | — | 135 | 150 | 5 |
EBITDA margin
1.3%
This company
15.8%
Market median
-92% vs market
20202024
Equity ratio
94.9%
This company
38.2%
Market median
+148% vs market
20202024
Return on equity
-3.9%
This company
18.4%
Market median
-121% vs market
20202024
Net profit margin
-1.9%
This company
8.1%
Market median
-123% vs market
20202024
Asset turnover
1.96×
This company
1.12×
Market median
+75% vs market
20202024
Debt / equity
0.05×
This company
0.62×
Market median
+92% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
FB Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of MedFer AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ferhat Baysal | Chief Executive Officer | 0 companies |
| Güven Baysal | Deputy Board Member | 0 companies |